“The United States is the biggest user of blood transfusions—approximately 5 million people in the U.S. receive blood and blood components through 10.9 million transfusions per year.” – Kalorama Information
The global $2.5 billion blood screening market is evolving on many levels, and despite it’s maturity the industry is poised for growth through 2026 due to new technologies, increased volume and increased testing in developing nations. This is according to data published in World Market for Blood Screening, the latest report by medical market research firm Kalorama Information. Blood screening is a medical process that scans the blood for infectious diseases or conditions. In developed nations, donated blood is screened for various pathogens.
Blood transfusions, important components of the blood screening market, have become so commonplace that it is easy to forget that blood is an organ, and the transfusion is akin to an organ transplant and should be performed only when absolutely necessary. This concept has led to some hospitals reevaluating their blood usage. They found that some 30%-50% percent of blood transfusions were medically non-beneficial and may even have contributed to clinical complications such as sepsis and myocardial injury.
On the other hand, the need to assure a safe transfusion service has increased the cost to produce a transfusion ready unit of blood and other blood products. Therefore, hospitals are encouraged to find a more effective way to manage their blood usage.
Nevertheless, the United States is the biggest user of blood transfusions—approximately 5 million people in the U.S. receive blood and blood components through 10.9 million transfusions per year, which is 44% higher than Canada and 15% higher than Europe per capita.
For more information on blood screening, blood transfusions, and related topics purchase Kalorama Information’s World Market for Blood Screening (published January 2022) at: https://kaloramainformation.com/product/world-market-for-blood-screening/.